STOK
Stoke Therapeutics Inc

977
Mkt Cap
$1.25B
Volume
1,285.00
52W High
$38.69
52W Low
$5.35
PE Ratio
34.58
STOK Fundamentals
Price
$22.82
Prev Close
$25.34
Open
$21.94
50D MA
$26.34
Beta
1.36
Avg. Volume
1.35M
EPS (Annual)
-$1.65
P/B
4.08
Rev/Employee
$285,585.94
Loading...
Loading...
News
all
press releases
All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·19h ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·2d ago
News Placeholder
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·7d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·21d ago
News Placeholder
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·27d ago
News Placeholder
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today...
Business Wire·28d ago
News Placeholder
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·28d ago
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest STOK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.